Bm. Meehan et al., INVESTIGATION OF THE ATTENUATION EXHIBITED BY A MOLECULARLY CLONED CHICKEN ANEMIA VIRUS ISOLATE BY UTILIZING A CHIMERIC VIRUS APPROACH, Journal of virology, 71(11), 1997, pp. 8362-8367
Molecular cloning of the Cux-1 isolate of chicken anemia virus (CAV),
which had been passaged 173 times in cell culture, resulted in the iso
lation of an attenuated strain, designated cloned isolate 10, which re
verted to virulence following 10 passages in young chicks (D. Todd, T.
J. Connor, V. M. Calvert, J. L. Creelan, B. M. Meehan, and M. S. McNu
lty, Avian Pathol. 24:171-187, 1995). The attenuated cloned isolate 10
differs from the molecularly cloned pathogenic Cux-1 isolate in that
it possesses a 21-nucleotide insertion within the nontranscribed regio
n of the CAV genome and 17 individual nucleotide substitutions dispers
ed throughout the genome, Comparative analyses with other published CA
V sequences indicated that cloned isolate 10 was unique at nine nucleo
tide positions and at five amino acid positions, The molecular basis o
f the attenuation exhibited by cloned isolate 10 was investigated by e
valuating the pathogenicities of two sets of complementary chimeric vi
ruses, These sets were produced by transfection with chimeric double-s
tranded replicative-form (RF) DNA equivalents that contained DNA seque
nces derived from cloned isolate 10 and the pathogenic cloned Cux-1 is
olate, The construction of the chimeric RFs exploited the occurrence o
f unique EcoRI, PstI, and BamHI restriction sites, which allowed their
respective circular CAV RFs to be manipulated as three restriction fr
agments of 0.58, 0.93, and 0.71 kbp. Examination of the levels of anem
ia and gross pathology in the thymuses and bone marrows of 14 day-old
specific-pathogen-free chicks following infection of 1-day old chicks
with the chimeric and cloned parental isolates indicated that nucleoti
de changes in each of the three genomic regions contributed towards at
tenuation. The significance of this result to the development and use
of live attenuated CAV vaccines is discussed.